skip to main content

Colchicine Dose Adjustment in CV Patients — EECC MCQ

Instant feedback + full explanation. One question, done properly.

HardCardiac PharmacologyColchicine Dose Adjustment in CV PatientsEECC

A patient taking verapamil and atorvastatin develops an acute gout flare. eGFR is 24 mL/min/1.73 m². Which feature most strongly argues against routine full-dose colchicine?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Renal failure plus verapamil makes colchicine hazardous

Colchicine has a narrow therapeutic index. Renal impairment reduces clearance, while verapamil inhibits P-glycoprotein and CYP3A4, increasing exposure; concomitant statin use also heightens concern for myotoxicity. A specialist should select an alternative or an appropriately reduced regimen after checking the product information and interactions. NSAIDs may be unsafe in advanced CKD, and corticosteroid therapy may be preferable after individual assessment. The original fixed dose ignored precisely the variables that make colchicine hazardous.

Reference: NICE NG219: gout diagnosis and management. https://www.nice.org.uk/guidance/ng219/chapter/Recommendations